Clinical commissioning policy: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)

Document first published:
Page updated:
Topic:
Publication type:

Obinutuzumab is recommended to be available off-label as a routine commissioning treatment option as elective therapy to prevent immune TTP relapse in patients who are intolerant or refractory to rituximab within the criteria set out in this document.